📊 BNTC Key Takeaways
Investment Thesis
Benitec Biopharma is a pre-revenue stage biopharmaceutical company with no commercial revenue and significant ongoing operating losses of $23.2M, indicating the company is in early-stage development without approved products generating sales. While the company maintains a strong cash position of $188.8M with minimal debt, the current burn rate of $7.1M in negative operating cash flow combined with zero revenue sustainability suggests the company has several years of runway but faces existential risk if development programs fail to advance successfully.
BNTC Strengths
- Exceptionally strong liquidity position with $188.8M in cash and 67.69x current ratio
- Zero debt burden providing financial flexibility for R&D investments
- Substantial stockholders equity of $187.4M backing the balance sheet
- Minimal liabilities at only $3.3M relative to total assets
BNTC Risks
- Complete absence of revenue generation indicating pre-commercialization stage with uncertain pipeline success
- Negative operating cash flow of $7.1M annually representing unsustainable cash burn without product approval
- Negative ROE of -11.1% and ROA of -10.9% showing value destruction for shareholders
- Pharmaceutical development risk where pipeline candidates may fail clinical trials or regulatory approval
- Extended timeline to potential profitability dependent on successful product development and market adoption
Key Metrics to Watch
- Operating cash burn rate and cash runway months remaining
- Clinical trial progression and regulatory milestones for pipeline candidates
- Total revenue upon first product commercialization and gross margins
- Operating expense trajectory and cash burn deceleration
- Insider transactions and capital raises indicating management confidence or dilution concerns
BNTC Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 67.69x current ratio provides a solid financial cushion.
BNTC Profitability Ratios
BNTC vs Healthcare Sector
How Benitec Biopharma Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BNTC Balance Sheet & Liquidity
BNTC 5-Year Financial Trend
5-Year Trend Summary: Benitec Biopharma Inc.'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-1.22 indicates the company is currently unprofitable.
BNTC Growth Metrics (YoY)
BNTC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | N/A | -$5.1M | $-0.48 |
| Q3 2024 | N/A | -$4.3M | $-1.64 |
| Q2 2024 | N/A | -$5.1M | $-0.33 |
| Q3 2023 | $48.0K | -$3.3M | $-0.16 |
| Q2 2023 | $14.0K | -$4.8M | $-0.20 |
| Q1 2023 | N/A | -$5.0M | $-0.47 |
| Q3 2022 | $1.0K | -$2.7M | N/A |
| Q2 2022 | $1.0K | -$2.7M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BNTC Capital Allocation
BNTC SEC Filings
Access official SEC EDGAR filings for Benitec Biopharma Inc. (CIK: 0001808898)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BNTC
What is the AI rating for BNTC?
Benitec Biopharma Inc. (BNTC) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BNTC's key strengths?
Exceptionally strong liquidity position with $188.8M in cash and 67.69x current ratio. Zero debt burden providing financial flexibility for R&D investments.
What are the risks of investing in BNTC?
Complete absence of revenue generation indicating pre-commercialization stage with uncertain pipeline success. Negative operating cash flow of $7.1M annually representing unsustainable cash burn without product approval.
What is BNTC's revenue and growth?
Benitec Biopharma Inc. reported revenue of $0.0.
Does BNTC pay dividends?
Benitec Biopharma Inc. does not currently pay dividends.
Where can I find BNTC SEC filings?
Official SEC filings for Benitec Biopharma Inc. (CIK: 0001808898) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BNTC's EPS?
Benitec Biopharma Inc. has a diluted EPS of $-0.48.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.